A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Biote Corp. stock. As of the latest transaction made, Citadel Advisors LLC holds 39,254 shares of BTMD stock, worth $237,094. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,254
Previous 75,588 48.07%
Holding current value
$237,094
Previous $564,000 61.17%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.33 - $8.36 $193,660 - $303,752
-36,334 Reduced 48.07%
39,254 $219,000
Q2 2024

Aug 14, 2024

BUY
$5.44 - $7.47 $411,198 - $564,642
75,588 New
75,588 $564,000
Q2 2023

Aug 14, 2023

BUY
$5.27 - $6.9 $83,034 - $108,716
15,756 New
15,756 $106,000

Others Institutions Holding BTMD

About biote Corp.


  • Ticker BTMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 7,574,270
  • Market Cap $45.7M
  • Description
  • biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biot...
More about BTMD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.